The number of small-molecule approvals declined more sharply than that of biologics over the past decade. However, new targets, such as atrium-specific K+ channel, phosphodiesterase-4 and renal Na+-glucose co-transporter, continue to open up new opportunities. Such novel targets are not without risk, as Eli Lilly found this quarter when its gamma-secretase inhibitor failed to meet its endpoints in Alzheimer's. Meanwhile, MannKind's inhaled insulin, Afrezza, demonstrated both efficacy and safety in a key trial. Approvals are also expected for Benlysta (belimumab), ipilimumab and Bydureon (exenatide LAR).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peng, W. Drug pipeline: Q310. Nat Biotechnol 28, 998 (2010). https://doi.org/10.1038/nbt1010-998
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1010-998
